Neuroimmune disorders such as autoimmune encephalitis, neuromyelitis optica spectrum disorders, myasthenia gravis, and immune-mediated peripheral neuropathy
Conditions
Interventions
Sponsors
Punan Hospital,Pudong New District, Shanghai
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnostic criteria: The clinical manifestations, cerebrospinal fluid, imaging findings, and immune treatment responses strongly support neuroantibody-mediated autoimmune diseases, including autoimmune encephalitis, neuromyelitis optica spectrum disorders, myasthenia gravis, and immune-mediated peripheral neuropathy, etc.; 2. Inclusion criteria: The results of routine + broad-spectrum + rare neuroantibody tests are all negative; Serum/plasma exchange fluid (=10ml) can be provided, and cerebrospinal fluid can be provided as well; 3. Those who can provide dynamic samples before, during, and after treatment are preferred for inclusion; The samples should be stored under standard conditions at -80?, without repeated freezing, hemolysis, or degradation; The clinical diagnosis and treatment data are complete, the background is clear, and they can meet the subsequent verification requirements.
Exclusion criteria
Exclusion criteria: 1. The diagnosis was made as non-immune neurological diseases such as infection, tumor, genetics, metabolism, poisoning, vascular, and traumatic disorders; 2. The samples were repeatedly frozen and thawed, hemolyzed, contaminated, or insufficient in quantity, making it impossible to complete the experiments; 3. The clinical data were severely lacking, making it impossible to determine the possibility of an immune cause; 4. After extensive antibody spectrum screening, it was confirmed as a positive result for known antibodies; 5. Dynamic samples before and after treatment could not be provided, or the ethical and informed consent was incomplete.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Novel neural autoantibody detection rate;TBA positivity rate;Candidate antigen validation success rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Association between antibodies and clinical phenotypes, treatment response, and prognosis;Dynamic changes in antibody levels before and after treatment; | — |
Countries
China
Contacts
Public ContactGuan Yangtai
Punan Hospital,Pudong New District, Shanghai
Outcome results
None listed